Market Place
Sourcing Support
Aurinia Presents LUPKYNIS Data At ASN Kidney Week 2024
11 Oct 2024 //
BUSINESSWIRE
Aurinia Announces Japan Approval of LUPKYNIS® for Lupus Nephritis
24 Sep 2024 //
BUSINESSWIRE
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
13 Sep 2024 //
BUSINESSWIRE
Aurinia Announces Board Restructuring
12 Sep 2024 //
BUSINESSWIRE
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
05 Sep 2024 //
BUSINESSWIRE
Aurinia To Participate In H.C. Wainwright Conference
28 Aug 2024 //
BUSINESSWIRE
Aurinia Shareholder Calls For CEO And Two Directors To Resign
13 Aug 2024 //
BUSINESSWIRE
Aurinia Reports Q2 And H1 2024 Financial And Operational Results
01 Aug 2024 //
BUSINESSWIRE
Aurinia To Release Q2 Results And Operational Update On August 1, 2024
19 Jul 2024 //
BUSINESSWIRE
ILJIN SNT Calls On Aurinia Board To Honor Shareholders` Voices From AGM
11 Jul 2024 //
BUSINESSWIRE
Aurinia to Participate in Upcoming Investor Healthcare Conferences
02 Jul 2024 //
BUSINESSWIRE
Aurinia Announces 2024 Annual General Meeting Results
14 Jun 2024 //
BUSINESSWIRE
ILJIN SNT To Vote Against Aurinia Revised Equity Incentive
07 Jun 2024 //
PR NEWSWIRE
Aurinia: LUPKYNIS Profile In Lupus Nephritis At EULAR 2024
05 Jun 2024 //
BUSINESSWIRE
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
04 Jun 2024 //
BUSINESSWIRE
Aurinia Provides Update on Proxy Statement
03 Jun 2024 //
BUSINESSWIRE
Shareholder Urges Withholding Support For Aurinia CEO Greenleaf
03 Jun 2024 //
BUSINESSWIRE
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
30 May 2024 //
BUSINESSWIRE
Analysis Shows LUPKYNIS Cost-Effective For Lupus Nephritis At NKF Meeting
14 May 2024 //
BUSINESSWIRE
Aurinia LUPKYNIS Lupus Nephritis Data At Rheumatology Congress
09 May 2024 //
BUSINESSWIRE
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
07 May 2024 //
BUSINESSWIRE
Aurinia Shareholder Urges Board Action To Enhance Value
07 May 2024 //
BUSINESSWIRE
Aurinia Reports Q1 2024 Financial, Operational Results
02 May 2024 //
BUSINESSWIRE
Aurinia Initiatives For Lupus Nephritis Awareness Month
01 May 2024 //
BUSINESSWIRE
Aurinia brings singer Toni Braxton to Lupus Awareness Month push
01 May 2024 //
FIERCE PHARMA
FDA Approves Updated LUPKYNIS® Label With Long-Term AURORA Data
30 Apr 2024 //
BUSINESSWIRE
Updated Aurinia Presentation At Bloom Burton Investor Conf 2024
16 Apr 2024 //
BUSINESSWIRE
Aurinia Q1 2024 Financials, Operations On 5/2
15 Apr 2024 //
BUSINESSWIRE
Aurinia Receives Exemptive Relief from Canadian Securities Regulators
29 Feb 2024 //
PRESS RELEASE
Aurinia to Participate in Upcoming Investor Healthcare Conferences
27 Feb 2024 //
BUSINESSWIRE
Aurinia stock downgraded by Bloom Burton amid strategic challenges
15 Feb 2024 //
PRESS RELEASE
Aurinia Discloses 2023 Year-End Financial and Operational Results
15 Feb 2024 //
BUSINESSWIRE
After hunt for buyer fails, Aurinia lays off 25%, drops R&D
15 Feb 2024 //
FIERCE BIOTECH
Aurinia to Release 2023 Fourth Quarter and Full Year Financial Results
05 Feb 2024 //
BUSINESSWIRE
Aurinia Provides Preliminary Unaudited Fourth Quarter Net Revenue Results
05 Jan 2024 //
BUSINESSWIRE
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
20 Dec 2023 //
BUSINESSWIRE
Aurinia Announces Collaboration Partner Otsuka Filed NDA for LUPKYNIS
13 Nov 2023 //
BUSINESSWIRE
Aurinia Reports Third Quarter and Nine Months 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Aurinia Presents Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS
02 Nov 2023 //
BUSINESSWIRE
Aurinia Response in Support of 2023 Updated EULAR Recommendations
26 Oct 2023 //
BUSINESSWIRE
Aurinia Pharma to Release Third Quarter Financial Results on November 2, 2023
19 Oct 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Announces Presentations at ASN Kidney Week 2023
13 Oct 2023 //
BUSINESSWIRE
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
21 Sep 2023 //
BUSINESSWIRE
Aurinia quells investor unrest, names former CEO Foster to board
21 Sep 2023 //
FIERCE PHARMA
Aurinia Appoints Board Directors with Deep Experience in BioPharma Leadership
21 Aug 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial
03 Aug 2023 //
BUSINESSWIRE
Aurinia BOD Announces Exploration of Alternatives to Maximize Shareholder Value
29 Jun 2023 //
BUSINESSWIRE
Aurinia will explore possible sale, following push by shareholder
29 Jun 2023 //
ENDPTS
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) a
20 Jun 2023 //
BUSINESSWIRE
LUPKYNIS Achieved Higher Renal Response in Lupus Nephritis Patients
01 Jun 2023 //
BUSINESSWIRE
Aurinia Files Form S-8 to Register Shares Underlying Disclosed Inducement Awards
26 May 2023 //
BUSINESSWIRE
Aurinia Announces 2023 Annual General Meeting Results
17 May 2023 //
BUSINESSWIRE
Aurinia’s board gets pushback from another shareholder
11 May 2023 //
ENDPTS
Aurinia Pharmaceuticals Reports 1Q 2023 Financial and Operational Results
04 May 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®
03 May 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
02 May 2023 //
BUSINESSWIRE
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” Company Director Nominees
28 Apr 2023 //
BUSINESSWIRE
Aurinia enlists Toni Braxton for lupus push after missing target
25 Apr 2023 //
FIERCE PHARMA
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable
25 Apr 2023 //
BUSINESSWIRE
